If You Invested in Aptose Bioscienc (APTOF)
Looking for the current price? See the APTOF quote & overviewWhat $1,000 or $10,000 in APTOF Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Apr 2, 2025 |
|---|---|---|---|---|
| $1,000 | $1,182 +18% | — | — | $841 -16% |
| $10,000 | $11,818 +18% | — | — | $8,408 -16% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-07-02. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for APTOF$1,000 Investment Over Time
APTOF vs S&P 500Year-by-Year Returns
APTOF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2025 | $2.01 | $1.48 | -26.4% | -26.4% |
| 2026 | $1.5385 | $1.69 | +9.8% | -15.9% |
About Aptose Bioscienc
Healthcare · OTC Link
Aptose Biosciences Inc. (APTOF) is a clinical-stage biotechnology company in the healthcare sector focused on oncology. According to multiple company disclosures, Aptose is developing precision medicines that address unmet medical needs in cancer, with an initial focus on hematology and hematologic malignancies. The company describes its work as centered on small molecule cancer therapeutics that can be used as single agents or in combination with other anti-cancer therapies and regimens without overlapping toxicities.
Aptose’s stock trades in the United States over-the-counter under the symbol APTOF and on the Toronto Stock Exchange under the symbol APS, as referenced in recent press releases and Form 8-K filings. The company is incorporated in Canada and files reports with both Canadian securities regulators and the U.S. Securities and Exchange Commission.
Core business focus
Across its public communications, Aptose consistently describes itself as a clinical-stage precision oncology company. Its primary goal is to develop targeted small molecule therapies for blood cancers. The company’s disclosures emphasize a focus on therapies that can:
- Address unmet medical needs in oncology, particularly in hematology
- Provide efficacy as single agents
- Enhance the efficacy of existing anti-cancer therapies and regimens
- Avoid overlapping toxicities when used in combination
Because Aptose is in the clinical stage, its activities are concentrated on research, development, and clinical trials rather than commercial product sales. Its public filings and news releases focus on clinical data, trial design, financing arrangements, and corporate transactions rather than marketed products.
Lead program: tuspetinib (TUS)
The company identifies tuspetinib (TUS) as its lead clinical-stage compound. Aptose describes tuspetinib as an oral kinase inhibitor that has demonstrated activity both as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML). In multiple news releases and in its quarterly updates, Aptose states that tuspetinib is being developed as part of a frontline triplet therapy in newly diagnosed AML.
Aptose reports that tuspetinib is being evaluated in the TUSCANY Phase 1/2 trial, a clinical study testing various doses and schedules of TUS in combination with standard dosing of azacitidine (AZA) and venetoclax (VEN) in newly diagnosed AML patients who are ineligible to receive induction chemotherapy. The company refers to this regimen as TUS+VEN+AZA and describes it as a triple drug frontline therapy intended to treat large, mutationally diverse AML populations, including patients with adverse genetic mutations.
According to Aptose’s disclosures, tuspetinib is a once-daily oral agent that targets SYK, mutated and wild type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases. The company highlights that tuspetinib is designed to avoid many toxicity concerns observed with other agents, and that in early clinical data from the TUSCANY trial, the TUS+VEN+AZA triplet has shown promising safety and antileukemic activity across diverse mutational subtypes, including patients with TP53, RAS, FLT3-ITD, NPM1c, and myelodysplasia-related mutations.
Clinical-stage pipeline and discontinued programs
Aptose’s disclosures describe a small molecule cancer therapeutics pipeline. Within its research and development expense breakdowns, the company identifies program costs for:
- Tuspetinib – the primary focus of current development spending, including the TUSCANY trial and related manufacturing and development activities
- Luxeptinib – a program that continues to incur clinical and manufacturing-related costs, though at a lower level than tuspetinib
- APTO-253 – a program for which the company states it has discontinued further development
These program references appear in Aptose’s quarterly financial results, where the company explains changes in research and development expenses by program. This provides insight into how Aptose allocates resources within its pipeline and which assets are currently prioritized.
Financial position and funding relationships
In recent quarterly updates, Aptose reports that it is a development-stage company with operating losses and negative shareholders’ equity. The company discloses that it does not have sufficient cash to fund operations and relies on financing arrangements to support ongoing clinical development.
Aptose highlights a significant funding relationship with Hanmi Pharmaceutical Co. Ltd. The company reports that Hanmi has participated in multiple financings and has provided debt facilities to support the continued development of tuspetinib, including a loan facility and an amended facility agreement administered through multiple advances. Aptose states that advances under these facilities are used to fund business and clinical operations expenses reasonably related to the advancement of tuspetinib.
Planned acquisition by Hanmi Pharmaceutical
Aptose has entered into a definitive arrangement agreement with Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd., a wholly owned subsidiary of Hanmi. According to the company’s November 2025 press release and corresponding Form 8-K, Hanmi Purchaser will acquire all of the issued and outstanding common shares of Aptose that are not already owned or controlled by Hanmi or its affiliates, subject to customary closing conditions.
Under the terms of this arrangement, minority shareholders of Aptose are expected to receive cash consideration per common share, and the transaction is structured as a plan of arrangement under the Business Corporations Act (Alberta) following a continuance from the Canada Business Corporations Act. Aptose states that completion of the transaction is subject to court approval and shareholder approval, including approval by a specified majority of votes and a separate majority of minority shareholders as required under Canadian securities rules.
The company indicates that, after completion of the transaction, it expects to no longer be subject to the reporting requirements of applicable Canadian securities legislation and that its common shares will be delisted from all stock exchanges
Regulatory reporting and exchanges
Aptose files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-32001 and with Canadian securities regulators. The company’s Form 8-K filings reference its Canadian incorporation and its reporting obligations. Aptose’s shares trade on the Toronto Stock Exchange under the symbol APS and on the OTCQB Market in the United States under the symbol APTOF, as noted in company news releases.
Clinical and scientific communications
The company frequently reports clinical data and trial progress at major hematology and oncology conferences. Recent disclosures describe presentations of tuspetinib data at:
- The European Hematology Association (EHA) Congress
- The European School of Haematology (ESH) 7th International Conference on Acute Myeloid Leukemia
- The American Society of Hematology (ASH) Annual Meeting
In these settings, Aptose has highlighted safety and efficacy data from the TUSCANY trial, including complete remission (CR/CRh) rates, minimal residual disease (MRD) negativity, and responses across diverse genetic subtypes of AML. The company also notes that tuspetinib can be administered with standard dosing of venetoclax and azacitidine and that no dose-limiting toxicities, prolonged myelosuppression in remission, or treatment-related deaths have been observed in the reported cohorts to date.
Corporate governance and auditors
Aptose discloses that its shareholders approved the appointment of Ernst & Young LLP (EY) as the company’s independent registered public accounting firm at a reconvened annual and special meeting. The company notes that EY is a global accounting firm with experience in the life sciences sector, and that this appointment followed a board decision to select EY as its new independent auditor.
Investment considerations and risk disclosures
In its press releases and Form 8-K filings, Aptose includes extensive forward-looking statements and risk factor discussions. The company cautions that its development programs, including tuspetinib and the TUSCANY trial, are subject to risks typical of early-stage drug development, such as demonstrating efficacy, regulatory approval processes, manufacturing, financing, and the ability to attract and retain key personnel. It also notes risks related to its financial position, reliance on external financing, and uncertainties around the completion of the announced transaction with Hanmi.
These disclosures underscore that Aptose remains a clinical-stage biotechnology company without approved commercial products, and that its value proposition is closely tied to the progress and outcomes of its clinical trials and corporate transactions.
How Aptose fits within biotechnology and hematology
Within the broader biotechnology sector, Aptose positions itself specifically in precision oncology for hematologic malignancies, with a central focus on acute myeloid leukemia. Its lead asset tuspetinib is intended to address both newly diagnosed AML patients who are ineligible for induction chemotherapy and patients with relapsed or refractory disease. The company’s emphasis on mutation-agnostic activity and combination regimens with existing standards of care reflects its stated goal of improving outcomes across diverse AML patient populations.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Aptose Bioscienc investment returns
How much would $1,000 invested in Aptose Bioscienc be worth today?
If you invested $1,000 in Aptose Bioscienc (APTOF) 1 years ago on 2025-07-29, your investment would be worth $1,182 as of 2026-07-02, representing a +18.2% total return, growing at a compounded rate of 19.8% per year (CAGR).
Has Aptose Bioscienc outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare APTOF performance over available time periods.
What is Aptose Bioscienc's average annual return?
The compound annual growth rate (CAGR) of APTOF over the past 1 years is 19.8%, growing at a compounded rate each year. Individual years vary significantly — APTOF's best recent year was 2026 (+9.8%) and worst was 2025 (-26.4%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
